Suprasomes Based on Host-Guest Molecular Recognition: An Excellent Alternative to Liposomes in Cancer Theranostics

Angew Chem Int Ed Engl. 2022 Dec 23;61(52):e202213572. doi: 10.1002/anie.202213572. Epub 2022 Dec 5.

Abstract

Liposomes and polymersomes, typical vesicular drug delivery systems (DDSs), have faced some limitations in cancer theranostics. Suprasomes, supramolecular vesicles assembled from amphiphiles linked by noncovalent interactions, show potential as new generation of vesicular DDSs. We construct suprasomes based on host-guest recognition, by which the desired functions can be integrated into carriers without tedious synthesis. Photothermally active host-guest complex is formed between a functional guest and pillar[5]arene, which further self-assembles into hollow suprasomes. A supramolecular nanomedicine is developed by encapsulating cisplatin in the suprasomes. The obtained cisplatin@Suprasomes achieve excellent anticancer efficacy and anti-metastasis combining chemotherapy and photothermal therapy, which ablate the tumors without relapse and metastasis. This work demonstrates the facile functionalization of suprasomes, holding promise as alternatives to liposomes and polymersomes.

Keywords: Cancer Theranostics; Drug Delivery System; Host-Guest Recognition; Supramolecular Chemistry; Vesicles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cisplatin
  • Drug Delivery Systems
  • Humans
  • Liposomes*
  • Neoplasms* / diagnostic imaging
  • Neoplasms* / drug therapy
  • Precision Medicine

Substances

  • Liposomes
  • Cisplatin